Home > Enanta Pharmaceuticals Salary

Enanta Pharmaceuticals Salary

  • 55
  • 81
  • 16
Enanta Pharmaceuticals average salary is $52,250, median salary is $52,250 with a salary range from $52,250 to $52,250.
Enanta Pharmaceuticals salaries are collected from government agencies and companies. Each salary is associated with a real job position. Enanta Pharmaceuticals salary statistics is not exclusive and is for reference only. They are presented "as is" and updated regularly.
Low
52,250
Average
52,250
Median
52,250
High
52,250
Total 1 Enanta Pharmaceuticals Salaries. Sorted by Date, page 1
Ranked By:
Job Title Salaries City Year More info
Database Analyst 52,250-52,250 Tulsa, OK, 74101 2013 Enanta Pharmaceuticals Database Analyst Salaries (1)
Enanta Pharmaceuticals Tulsa, OK Salaries
Calculate how much you could earn

It's FREE. Based on your input and our analysis.     How we do it?

All fields are required for calculation accuracy.

  • We will send you an email to access your personalized report.
  • We won’t share your email address

Enanta Pharmaceuticals salary is full-time annual starting salary. Intern, contractor and hourly pay scale vary from regular exempt employee. Compensation depends on work experience, job location, bonus, benefits and other factors.

Real Jobs Salary - Salary List
Calculate Your Salary Ranking
Enanta Pharmaceuticals Jobs
See more Enanta Pharmaceuticals Jobs»
Search All Jobs

JobCompare – Find open jobs faster
Patents information
1706

All Patents

411

Grant Patents

1158

Patents Pending

559

Patents Families

More Recent
Enanta Pharmaceuticals... Information
  • Enanta Pharmaceuticals, Inc
  • Industry: BioTech/Drugs
  • City: Watertown, MA
  • To Accelerate Drug Discovery by Focusing on Transforming Existing Drugs, Natural Products, and Biologically Active Peptide Leads into Small Molecules with Improved Pharmacological Properties ...At the heart of our company is its strong commitment to state-of-the-art and innovative chemistries that transcend traditional medicinal chemistry approaches in their use of the latest synthetic methodology, novel catalysts and stereochemically controlled library synthesis. Our primary strength lies in the integration of chemistry and biology. Our goal is to tackle new targets and specific drug development problems from all possible angles right from the start. This comprehensive approach will ultimately shorten the time between